3D Contrast MR Angiography

Prince, Martin R.; Grist, Thomas M.; Debatin, Jörg F.

doi:10.1007/978-3-662-03414-9

Cited by 68 publications

(61 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many investigators now use a ''double dose'' (0.2 mmol/ kg) of gadolinium chelate with injection rates of 1-2 cc/s, whereas some use up to a ''quadruple dose'' (0.4 mmol/kg) and rates of 4-5 cc/s [13,52,54,64,65]. We personally feel that ''double dose'' with an injection rate of about 2 cc/s is a good compromise between maximal arterial signal and minimal artifacts for breath-hold scans [66].…”

Section: Contrast Materials Injection Ratementioning

confidence: 98%

“…Such artifacts mainly consist of underestimating vessel lumen and are more of a problem with TOF or PC techniques. Because of these potential pitfalls, most investigators agree that the MIP images should be used as a roadmap and use the source images for definitive diagnosis [1,81,84].…”

Section: Postprocessing and Displaymentioning

confidence: 99%

“…Because these reformatted slices remain thin and are not projections, they not only provide the best achievable contrast but also minimize the chance of diagnostic error when used diligently (see Fig. 8B) [1,81].…”

Section: Postprocessing and Displaymentioning

confidence: 99%

“…For a representative acquisition matrix size of 256 1 160 1 32, this volume produces voxels 1.25 1 2.0 1 2.0 mm in size. For diagnostic purposes, this dataset is best viewed interactively using a computer workstation allowing for thin multiplaner reformatting [1,81]. In this manner, thin (1.25-2.0 mm in this case) slices can be viewed in axial, sagittal, coronal, or oblique planes, thus eliminating overlapping structures and unfolding tortuous ves- sels.…”

Section: Postprocessing and Displaymentioning

confidence: 99%

See 3 more Smart Citations

Contrast-enhanced MR angiography

1998

View full text Add to dashboard Cite

show abstract

Section: Contrast Materials Injection Ratementioning

confidence: 98%

Section: Postprocessing and Displaymentioning

confidence: 99%

Section: Postprocessing and Displaymentioning

confidence: 99%

Section: Postprocessing and Displaymentioning

confidence: 99%

See 2 more Smart Citations

Contrast-enhanced MR angiography

1998

View full text Add to dashboard Cite

show abstract

“…The increase in relaxivity or the reduction in T is 1 based on the concentration and the relaxivity of the paramagnetic contrast material and is given Ž . by40,41 …”

mentioning

confidence: 99%

Body vascular MR angiography: Using 2D- and 3D-time-of-flight techniques

Shetty

Bis

Shirkhoda

2000

Concepts Magn. Reson.

View full text Add to dashboard Cite

Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography

Taylor

Panting

Keegan

et al. 1999

J. Magn. Reson. Imaging

137

View full text Add to dashboard Cite

In this Phase I clinical study, a novel ultrasmall superparamagnetic iron oxide contrast agent, NC100150 Injection (Nycomed Imaging, Oslo, Norway, a part of Nycomed Amersham), was used in two-dimensional magnetic resonance coronary angiography (MRCA). Safety and imaging data were acquired from 18 healthy male volunteers at both 0.5 and 1.5 T, before and after the administration of NC100150 Injection. Through-plane and in-plane images of the right coronary artery were analyzed. The postcontrast imaging sequences used prepulses and a high flip angle, to introduce T1 weighting. At 1.5 T (TE 2.6 msec), the throughplane coronary artery signal-to-noise ratio (SNR) (P ‫؍‬ 0.04), coronary artery-to-fat signal difference-to-noise ratio (SDNR) (P ‫؍‬ 0.001), coronary artery-to-myocardium SDNR (P F 0.001), and coronary artery delineation (P F 0.001) were improved by the administration of NC100150 Injection. For in-plane imaging, coronary artery delineation improved, but there were no significant changes in the SNR and SDNR. At 0.5 T, with the longer TE (6.7 msec) imaging sequence used, there was a reduction in the SNR (P ‫؍‬ 0.01), the fat SDNR (through-plane P ‫؍‬ 0.02; in-plane P ‫؍‬ 0.25), and the coronary artery diameter (P F 0.01 in both imaging planes). There was a trend toward improvement in the myocardial SDNR and coronary artery delineation. In conclusion, NC100150 Injection was given safely to 18 healthy subjects, with no major adverse reactions. Coronary artery delineation was improved in both imaging planes at 1.5 T, with a trend toward improvement at 0.5 T. At 1.5 T, with a short TE imaging sequence, the marked T1 shortening effects of NC100150 Injection were dominant, leading to an improvement in the quantitative parameters for the through-plane images. At 0.5 T, with a longer TE imaging sequence, the T2* effects of the contrast agent played a role in reducing the quantitative image parameters. With further optimization of imaging sequences, to take advantage of the long-lived intravascular T1 shortening effect of NC100150 Injection, further improvements in MRCA will be possible.

show abstract

3D Contrast MR Angiography

Cited by 68 publications

References 0 publications

Contrast-enhanced MR angiography

Contrast-enhanced MR angiography

Body vascular MR angiography: Using 2D- and 3D-time-of-flight techniques

Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography

Contact Info

Product

Resources

About